InvestorsHub Logo
Followers 377
Posts 18023
Boards Moderated 3
Alias Born 04/29/2015

Re: None

Wednesday, 01/04/2017 10:03:06 AM

Wednesday, January 04, 2017 10:03:06 AM

Post# of 22858
$MEDH - MedX Pharma > 28mil outstanding shares as of last Q **4mil float**

Only $10,000 convertible debt shown in filings.
Bottom page 4 shows Roberton holds 80% all restricted..

MedX Pharma - licensed in Alabama as manufacturer, repackage, wholesale distributor of pharmaceuticals & is in process of licensing in the rest of the states.

Structured agreement - to distribute AMNEAL PHARMACEUTICALS recently ANDA approved "RX 5% lidocaine ointment" and recently FDA approved "1.5% generic diclofenac solution" to third party.

& three unspecified over the counter drugs, two manufactured by MedX, and the other through strategic agreement with GEMINI LABORATORIES for its fda approved over the counter drugs.

Licensing Update: In Florida, the company will ship directly to a Third Party Logistic partner who will legally ship to all of the clients in Florida. A Third Party Logistic Warehouse represents the fastest path for MEDH to legally sell in the state of Florida.


On May 17, 2016, MEDH announced that it is in the process of becoming licensed as a Wholesale Distributor of Pharmaceuticals in the state of Alabama. As a result, the company has also entered into an Exclusive Marketing Agreement with B&B Consulting whose sales exceeded over $7,000,000 dollars in pharmaceutical sales in 2015.

In addition, MEDH has also secured an agreement with one of the largest FDA Manufacturers in the United States. Our first product that has been approved to sell is a 5% Lidocaine Ointment 50g jar. Our negotiated price allows us to have very competitive pricing to offer B&B’s current list of clients.


MEDH is introducing, Collaborative Profit, an innovative approach that allows each acquisition to become a stand-alone subsidiary with all the advantage and power of public company while keeping their independent management control. This unique diversified platform, designed by MEDH, offers protection for both the investor and the subsidiary. It provides acquisitions the ability to raise capital and offers investors the assurance that their investment is at low risk.